TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00966628
Drug: Ringer's lactate
Normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer lactate infused at dose 20 mL/kgBW within 15 minutes to restore hemodynamic status. If shock state did not recover with first infusion, study fluid infused again at same dose. After recovery from shock, patient received maintenance dose of RL. In case of repeated shock, patients received HES (Hydroxy-Ethyl Starch) infusion at dose of 20 mL/kgBW/15-30 min with maximum dose of 50 mL/kgBW/24 hours.
Study: NCT04416854
Drug: XELOX
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxaliplatin 130mg/m2 ivgtt d1 and capecitabine 1000mg/m2,bid,po,d1-d14,every three weeks for a cycle
Study: NCT04416854
Drug: mFOLFOX6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin 85mg/m2, leucovorin 400mg/m2 ivgtt d1 and 5-FU 400 mg/m2 IV bolus d1，2400 mg/m2 CIV 46h, d1
Study: NCT03655977
Drug: 68Ga-NODAGA-E[c(RGDyK)]2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 MBq 68Ga-NODAGA-E\[c(RGDyK)\]2 will be administered before external beam radiation therapy (EBRT).
Study: NCT03655977
Drug: 68Ga-NODAGA-E[c(RGDyK)]2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 MBq 68Ga-NODAGA-E\[c(RGDyK)\]2 will be administered before brachytherapy (BT).
Study: NCT03142620
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500mg twice daily
Study: NCT03113396
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo oral, tid for 2 weeks after 2 weeks, patients undergo a High Resolution Impedance Manometry measurement with a meal period. Patients will fill out questionnaires concerning overall wellbeing.
Study: NCT00935805
Drug: NPH insulin
Normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Variable SC dose
Study: NCT00934973
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: overencapsulated placebo tablets 1 tds for 6 weeks
Study: NCT02709785
Drug: Placebo rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects use placebo mouth rinse for six weeks. The placebo rinse is the same as SmartMouth Clinical DDS, but without the active ingredients.
Study: NCT01976780
Drug: Artemether Lumefantrine
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02885441
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketorolac, 10 mg, 3 times daily from time of enrollment until 72 hours from enrollment. For up to a maximum of 9 doses.
Study: NCT03742063
Drug: first-line chemotherapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients who routinely received neoadjuvant chemotherapy according to Peking University People's Hospital chemo-protocols (PKUPH-OS and PKUPH-ES)
Study: NCT02450058
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 mg/m2, intravenously on day 1, every 21 days for six cycles
Study: NCT02821858
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be administered.
Study: NCT04553406
Drug: SPR720
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules for oral administration
Study: NCT04553406
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules for oral administration
Study: NCT02623738
Drug: Placebo ophthalmic solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02870231
Drug: NNC9204-0530
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily subcutaneous (s.c., under the skin) administration.
Study: NCT02870231
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily subcutaneous (s.c., under the skin) administration
Study: NCT04553406
Drug: Open-label Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of Care regimen is at the Investigator's discretion; recommended 2-drug or 3-drug SOC, consisting of either:~* Clarithromycin 500-1000 mg, plus ethambutol hydrochloride (HCl) 15 mg/kg orally once daily or~* Azithromycin 250-500 mg plus ethambutol HCl 15 mg/kg orally once daily.~Optional rifampin 600 mg or rifabutin 300 mg orally once daily may be added to the SOC regimen for up to 28 days.
Study: NCT01240850
Drug: Methotrexate+Prednisone
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate will be added at a dose of 0.3 mg/kg/week (maximum dose, 20 mg/week, orally) to a reduced-dose prednisone regimen
Study: NCT03341260
Drug: Diclofenac Potassium 50mg Tab.
Approvals — FDA: no, EMA: no, PMDA: no
Description: A 50 mg tablet of the medication to be taken one hour before initiation of endodontic treatment.
Study: NCT03341260
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo will be taken one hour before initiation of endodontic treatment.
Study: NCT00317148
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule
Study: NCT00789776
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00075959
Drug: NXY-059
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01676844
Drug: Oral thin film therapy (Potassium acid phosphate oral thin films)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally dissolving thin film. White, square oral thin film. 15 mm x 15 mm surface area. 1-2 mm film thickness. No markings.~Place a single OTF on the tongue, inside cheek or palate and allow to dissolve.
Study: NCT01676844
Drug: Standard therapy (Potassium acid phosphate oral solution)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each millilitre contains approximately 136mg Monobasic Potassium Phosphate Ph.Eur. (KH2PO4) equivalent to 1mmol Potassium (39mg) and 1mmol Phosphate (31mg Phosphorus). Manufacturer: Specials Products Ltd., Surrey, UK.
Study: NCT03949374
Drug: CRESTOR, reference formulation of rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of ROVASRO for hypercholesterolemia
Study: NCT02484508
Drug: Kangguzengsheng capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kangguzengsheng capsule, as the active comparator, is taken 3 grains each time, 3 time per day
Study: NCT03949374
Drug: ROVASRO, generic formulation of rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of CRESTOR for hypercholesterolemia
Study: NCT01132417
Drug: In Vitro activity of Tigecycline among key bacterial pathogens exhibiting multidrug resistance
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: studies in human beings in which biomedical and/or health outcomes are assessed in pre-defined groups of individuals. Subjects in the study may receive diagnostic, therapeutic, or other interventions, but the investigator does not assign specific interventions to the subjects of the study.
Study: NCT01214239
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once a day
Study: NCT01025791
Drug: MK-8266 0.1 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral doses of 0.1 to 1.2 mg of MK-8266 in 0.1 capsule form. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant. Some participants will receive study drug with food.
Study: NCT01025791
Drug: MK-8266 1.0 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-8266 1.0 mg oral capsule. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant.
Study: NCT00834613
Drug: Glucophage® XR 750 mg Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 750 mg, single-dose fed
Study: NCT04036409
Drug: Standard control of Systolic Blood Pressure (SBP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The same medications used in the Intensive BP arm will be used for the Standard BP arm.
Study: NCT01319968
Drug: Estriol 0.1% vaginal cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with both vulvovaginal atrophy (according to cytologic criteria) and dyspareunia will apply 0.5 ml of the cream (0.5 mg) to the vulvar vestibule once daily for one month and will return for check-up visit. In case both atrophy and dyspareunia will resolve, treatment with the cream will be continued 3 times a week.
Study: NCT01025791
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match MK-8266 0.1 or 1.0 mg. Participants will fast for 8 hours prior to dosing. There will be at least a 7- day washout period between doses for any given participant.
Study: NCT02258880
Drug: SUN13837
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02258880
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02401737
Drug: NVR 3-778
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02401737
Drug: Placebo for NVR 3-778
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill manufactured to mimic the NVR 3-778 capsule
Study: NCT03204123
Drug: Ga-HBED-iPSMA PET
Normalized name: Pet-ema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be injected with 100-300 MBq of 68Ga-HBED-iPSMA and after a waiting of 60-90 minutes patients will be scanned from mid-skull to mid-thigh.
Study: NCT03646162
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02950233
Drug: NMDA placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: NMDA active group will involve normal saline (IV bolus pre-incision and infusion postoperatively up to 24 hours) and oral matching placebo to memantine (1 capsule BID \[first week\]; 1 capsule BID \[following three weeks\]).
Study: NCT02950233
Drug: Steroid placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid placebo group will involve two doses of normal saline; one dose given prior to starting surgery and one dose given on the morning of second postoperative day.
Study: NCT04573309
Drug: ALXN1840
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally as tablets.
Study: NCT03516487
Drug: SYNB1618
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYNB1618 is supplied in a buffered solution in 5 mL polypropylene cryovials with a nominal 5 mL fill volume, administered with 100 mL of masking buffer solution.
Study: NCT03516487
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects receive placebo orally in a chilled buffered solution (100 mL).
Study: NCT00660387
Drug: Levodopa carbidopa intestinal gel (LCIG)
Normalized name: carbidopa / levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa/hour)
Study: NCT00660387
Drug: Placebo Gel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00660387
Drug: Levodopa-carbidopa (LC) oral encapsulated immediate release (IR) tablets
Normalized name: carbidopa / levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00666354
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 0.01 gram of topical amphimatrix containing 0.05% methotrexate per affected nail and adjacent skin folds applied daily for three months.
Study: NCT00666354
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 0.01 gram of topical amphimatrix containing 1.0% methotrexate per affected nail and adjacent skin folds applied daily for three months.
Study: NCT01482221
Drug: AZD6765 iv
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg (AZD6765 Solution for Infusion, 0.5 mg/mL) by iv infusion.
Study: NCT01482221
Drug: AZD6765 iv
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg (AZD6765 Solution for Infusion, 1.0 mg/mL) by iv infusion.
Study: NCT01482221
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 sodium chloride \[normal saline\] solution for injection by iv infusion
Study: NCT00814957
Drug: GSK618334
Approvals — FDA: no, EMA: no, PMDA: no
Description: D3 receptor antagonist
Study: NCT00090545
Drug: BAY 43-9006
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg BAY 43-9006 orally twice daily in 28 day cycles.
Study: NCT04019574
Drug: CR845 0.5 mcg/kg IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mcg/kg IV CR845
Study: NCT04019574
Drug: CR845 3 mcg/kg IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mcg/kg IV CR845
Study: NCT03786692
Drug: Arm A
Normalized name: Warm antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin + Pemetrexed + Bevacizumab + Atezolizumab
Study: NCT03786692
Drug: Arm B
Normalized name: arm brace
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin + Pemetrexed + Bevacizumab
Study: NCT04438044
Drug: ICP-022
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICP-022 The drug product is a white, round, uncoated tablet
Study: NCT04355598
Drug: placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL of the placebo cream will be placed on the anterior lip of the cervix by a Q-tip applicator, followed by 2 mL will be introduced in the cervical canal 7 minutes prior to IUD insertion
Study: NCT04654429
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Normal Saline 2cc will be given
Study: NCT03143049
Drug: PCD
Normalized name: Eyefull PCD Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: For PCD, patients will be treated as follows: PO pomalidomide 4mg from D1-21, PO cyclophosphamide 400mg on D1, 8 and 15, and PO or IV dexamethasone 40mg D1, 8, 15 and 22 in a 28-day cycle.~Patients will be assessed every 28 days (+/- 10 days). Patients shall receive the treatment until disease progression, unacceptable toxicity as determined by treating physician, withdrawal of consent or mortality (whichever occurs first).
Study: NCT03143049
Drug: PD
Normalized name: PDO
Approvals — FDA: no, EMA: no, PMDA: no
Description: For PD, Patients will be treated as follows: PO pomalidomide 4mg from D1-21 and PO or IV dexamethasone 40mg D1, 8, 15 and 22 in a 28-day cycle.~Patients will be assessed every 28 days (+/- 10 days). Patients shall receive the treatment until disease progression, unacceptable toxicity as determined by treating physician, withdrawal of consent or mortality (whichever occurs first).
Study: NCT01679041
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide is given 3 gm/m2 for mobilization, and then repeated during 5 day conditioning regimen w/ doses of 50mg/kg/day on days 1-4
Study: NCT01896479
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03321123
Drug: MB-CART19.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miltenyi Biotec has established a semi-automated manufacturing process that can be made available to academic settings for systematic exploration of CAR strategies in advanced clinical studies. Closed-system operation, improved robustness, simplified work flows, and reduced labor intensity, while maintaining strict adherence to regulatory guidelines, allows for decentralized manufacturing. In this study, we will explore autologous 2nd generation CD19 CAR T cell products in patients with relapsed and refractory disease incurable with standard therapies.
Study: NCT02117648
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally
Study: NCT02769624
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 breaths of placebo (via inhalation devices) will be administered 3 times: at baseline, 1.5 hrs. post baseline and then again 2 hrs later following maximal exercise testing.
Study: NCT01896479
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05311540
Drug: Zinc Sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00523991
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral inhalation once daily of placebo matching tiotropium via handihaler
Study: NCT01197287
Drug: QAK423A
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04419584
Drug: Modified Qing-Ying Decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal granules
Study: NCT04419584
Drug: Identical looking placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo granules
Study: NCT02246660
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be taken orally for 6 months.
Study: NCT01963481
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00354601
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral capecitabine twice daily on days 1-21
Study: NCT00131846
Drug: Thiazide diuretics
Normalized name: althiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any dosage, frequency, and duration
Study: NCT00691704
Drug: Sequential Maintenance Therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects who achieve \>partial response (PR) following induction therapy will receive repeating triplet cycles of alternating low dose therapy until progression, poor tolerance or toxicity. Subjects who complete 24 months of maintenance will be removed from study unless they achieved \> stable disease (SD) from maintenance (per discussion with physician):~* 325 mg aspirin for deep vein thrombosis (DVT) prophylaxis~* Cycle 1, 4, 7, etc. - bortezomib 1.3 mg/m2 on day 1 and 8 of a 28-day cycle~* Cycle 2, 5, 8 etc. - Melphalan 6 mg/m2 by mouth (po) daily on Days 1-7~* Prednisone 60 mg /m2 po daily on Days 1-7 of a 28-day cycle~* Cycle 3, 6, 9, etc. Lenalidomide 10 mg po daily on Days 1-21 of a 28 day cycle.
Study: NCT00131846
Drug: No diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any antihypertensive regimen other than diuretics
Study: NCT03450083
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous placebo injection
Study: NCT01819779
Drug: Exforge tab. 10/160mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01819779
Drug: Lodivixx tab. 5/160mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00151671
Drug: Oral Impact®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nutritional supplement containing L-arginin, ω3 polyunsaturated fatty acids, and nucleotides. Given three times a day for the 7 last preoperative and the first 3 postoperative days.
Study: NCT00151671
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution of placebo. Given three times a day for the 7 last preoperative and the first 3 postoperative days.
Study: NCT02669732
Drug: DS-8500a
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets
Study: NCT02669732
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets
Study: NCT01832987
Drug: co-trimoxazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: On 4, 5 or 6 consecutive days, co-trimoxazole 960 mg will be added to the normal treatment regimen
Study: NCT00859040
Drug: SOM230C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection in the buttocks every 28 days
Study: NCT00697762
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet twice daily for 12 weeks
Study: NCT04523480
Drug: Testopel 75mg Drug Implant
Normalized name: testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg Testosterone pellets administered subcutaneously.
Study: NCT04523480
Drug: Testopel 100mg Drug Implant
Normalized name: testosterone Drug Implant [Testopel]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg Testosterone pellets administered subcutaneously.
Study: NCT04523480
Drug: Testopel 200mg Drug Implant
Normalized name: testosterone Drug Implant [Testopel]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg Testosterone pellets administered subcutaneously.
Study: NCT04059978
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo p.o, single oral dose (8 ml oily solution)
Study: NCT04059978
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remifentanil 0.1 µg/kg/min i.v. for 30 min
Study: NCT01103648
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets of simvastatin 20 mg administered once a day for 12 weeks
Study: NCT04516096
Drug: AMX0035
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tauroursodeoxycholic Acid and Sodium Phenylbutyrate orally given twice a day
Study: NCT02689778
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical tablets without active substance
Study: NCT01103648
Drug: Combination Simvastatin plus Ezetimibe
Normalized name: ezetimibe / simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 mg, once a day, was administered for an additional 12-week period for the subset of individuals who took the initial monotherapy with ezetimibe 10 mg (12 week duration).~Ezetimibe 10 mg, once a day, was administered for an additional 12-week period for the subset of individuals who took the initial monotherapy with simvastatin 20 mg (12 week duration).~This Combination represents the experimental period of the present study.
Study: NCT00005589
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03091634
Drug: xue-fu-zhu-yu capsule
Normalized name: fu ling
Approvals — FDA: no, EMA: no, PMDA: no
Description: participants are given to 6 xue-fu-zhu-yu capsule per time, twice a day. The duration is 7 weeks
Study: NCT03091634
Drug: xue-fu-zhu-yu capsule simulated agent
Normalized name: fu ling
Approvals — FDA: no, EMA: no, PMDA: no
Description: participants are given to 6 xue-fu-zhu-yu capsule simulated agent per time, twice a day. The duration is 7 weeks
Study: NCT01606436
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT01220843
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: dosage : 2 tablets 3 times per day corresponding taken during meals during 12 weeks
Study: NCT00002923
Drug: KRN5500
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00459953
Drug: Extended treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants receive an open label phase treatment that includes nicotine patch and cognitive behavior therapy for a period of 10 weeks. The extended treatment group received an additional 9 sessions of cognitive and behavioral skills training.